Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
luseogliflozin + ranibizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravitreal
01
Overview
This is a combination therapy consisting of luseogliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, and ranibizumab, an intravitreal anti–vascular endothelial growth factor A (VEGF-A) monoclonal antibody fragment. The combination is investigated for the treatment of diabetic macular edema (DME) in patients with type 2 diabetes mellitus. Luseogliflozin lowers blood glucose by inhibiting renal glucose reabsorption, while ranibizumab inhibits VEGF-A to reduce vascular permeability and pathological angiogenesis in the retina. The rationale for this combination is to address both systemic metabolic dysfunction and local retinal pathology in DME, potentially reducing the frequency of intravitreal injections required for disease control[1][2][4].
- Other names
- luseogliflozin + ranibizumab
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on luseogliflozin + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on luseogliflozin + ranibizumab.